Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Paying user area
Try for free
Thermo Fisher Scientific Inc. pages available for free this week:
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Thermo Fisher Scientific Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Return on Invested Capital (ROIC)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | ||||||
| Invested capital2 | ||||||
| Performance Ratio | ||||||
| ROIC3 | ||||||
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2025 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × ÷ =
4 Click competitor name to see calculations.
The period under review demonstrates a fluctuating pattern in Return on Invested Capital (ROIC). Initially, a decline in ROIC is observed, followed by a modest recovery and subsequent increase. Net operating profit after taxes (NOPAT) and invested capital both exhibit changes over the five-year period, influencing the overall ROIC performance.
- ROIC Trend
- ROIC began at 9.42% in 2021, representing the highest value within the observed timeframe. A decrease was noted in 2022, falling to 7.76%, and continued downward in 2023, reaching 5.98%. A slight recovery occurred in 2024, with ROIC increasing to 6.58%. This upward trend continued into 2025, with ROIC reaching 6.87%.
- NOPAT Analysis
- NOPAT decreased from US$7,514 million in 2021 to US$6,425 million in 2022, and further declined to US$5,117 million in 2023. A modest increase to US$5,400 million was recorded in 2024, followed by a more substantial increase to US$6,467 million in 2025. The fluctuations in NOPAT directly impact the ROIC calculation.
- Invested Capital Analysis
- Invested capital generally increased over the period, rising from US$79,776 million in 2021 to US$82,814 million in 2022 and US$85,573 million in 2023. A decrease was observed in 2024, with invested capital falling to US$82,071 million. A significant increase occurred in 2025, reaching US$94,150 million. The growth in invested capital, coupled with NOPAT changes, contributes to the observed ROIC trends.
The interplay between NOPAT and invested capital suggests that while the company has been increasing its capital base, its ability to generate profit from that capital has varied. The recovery in ROIC in 2024 and 2025 coincides with increases in NOPAT, indicating a positive correlation between profitability and returns on invested capital. The substantial increase in invested capital in 2025 warrants further investigation to determine its impact on future ROIC performance.
Decomposition of ROIC
| ROIC | = | OPM1 | × | TO2 | × | 1 – CTR3 | |
|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | = | × | × | ||||
| Dec 31, 2024 | = | × | × | ||||
| Dec 31, 2023 | = | × | × | ||||
| Dec 31, 2022 | = | × | × | ||||
| Dec 31, 2021 | = | × | × |
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The period under review demonstrates fluctuations in the key drivers of return on invested capital. Overall, ROIC experienced a decline from 2021 to 2023, followed by a modest recovery in the subsequent two years. This analysis details the observed trends in operating profit margin, capital turnover, and the impact of the effective cash tax rate on ROIC.
- Operating Profit Margin (OPM)
- A decreasing trend in operating profit margin is evident from 2021 to 2023, declining from 23.92% to 15.91%. A slight recovery is then observed in 2024 and 2025, reaching 17.13% and 17.41% respectively. This suggests potential pressures on profitability during 2022 and 2023, followed by some stabilization and improvement.
- Turnover of Capital (TO)
- The turnover of capital exhibited an initial increase from 0.49 in 2021 to 0.54 in 2022, indicating improved efficiency in asset utilization. However, this was followed by a decrease to 0.50 in 2023 and a further decline to 0.47 in 2025. This suggests a weakening in the ability to generate sales from invested capital in the later years of the period.
- Effective Cash Tax Rate Adjustment (1 – CTR)
- The factor representing one minus the effective cash tax rate generally decreased from 80.11% in 2021 to 73.51% in 2024, indicating a higher effective tax burden. A notable increase to 83.37% is then observed in 2025, suggesting a reduction in the effective tax rate and a positive impact on after-tax returns.
- Return on Invested Capital (ROIC)
- ROIC mirrored the combined effects of the aforementioned factors. The initial decline from 9.42% in 2021 to 5.98% in 2023 reflects the negative influence of decreasing operating profit margin and fluctuating capital turnover. The subsequent increase to 6.87% in 2025 is attributable to the combined effect of a slightly improved operating profit margin and a significant increase in the adjustment for the effective cash tax rate, partially offsetting the continued decline in capital turnover.
In summary, the observed ROIC trend is a result of interplay between profitability, asset utilization, and tax efficiency. While profitability showed some recovery towards the end of the period, the declining capital turnover presents a potential area of concern. The significant shift in the effective cash tax rate adjustment in 2025 had a notable positive impact on ROIC.
Operating Profit Margin (OPM)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | ||||||
| Add: Cash operating taxes2 | ||||||
| Net operating profit before taxes (NOPBT) | ||||||
| Revenues | ||||||
| Profitability Ratio | ||||||
| OPM3 | ||||||
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2025 Calculation
OPM = 100 × NOPBT ÷ Revenues
= 100 × ÷ =
4 Click competitor name to see calculations.
The operating profit margin exhibited a declining trend from 2021 to 2023, followed by a period of stabilization and slight improvement through 2025. Net operating profit before taxes also demonstrated volatility over the analyzed period.
- Operating Profit Margin (OPM)
- The operating profit margin decreased from 23.92% in 2021 to 18.33% in 2022, representing a substantial contraction. This decline continued into 2023, reaching a low of 15.91%. A modest recovery was then observed in 2024, with the margin increasing to 17.13%. This upward movement persisted into 2025, with the operating profit margin reaching 17.41%.
- Net Operating Profit Before Taxes (NOPBT)
- Net operating profit before taxes decreased from US$9,379 million in 2021 to US$8,231 million in 2022. A more significant decrease occurred in 2023, falling to US$6,818 million. The value increased to US$7,346 million in 2024, and further to US$7,757 million in 2025, though it did not return to the levels seen in 2021.
- Relationship between OPM and NOPBT
- The decrease in NOPBT from 2021 to 2023 aligns with the observed decline in the operating profit margin. While NOPBT increased in both 2024 and 2025, the operating profit margin experienced only incremental improvements. Revenues remained relatively stable between 2023 and 2025, suggesting that the increases in NOPBT during those years were primarily driven by cost management or efficiency gains rather than significant revenue growth.
Overall, the period was characterized by initial margin compression, followed by a stabilization and slight recovery in profitability. The relationship between revenues and NOPBT suggests a focus on operational efficiency in the later years of the analyzed period.
Turnover of Capital (TO)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenues | ||||||
| Invested capital1 | ||||||
| Efficiency Ratio | ||||||
| TO2 | ||||||
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Invested capital. See details »
2 2025 Calculation
TO = Revenues ÷ Invested capital
= ÷ =
3 Click competitor name to see calculations.
The analysis reveals fluctuations in the turnover of capital over the five-year period. Revenues exhibited an initial increase followed by a slight decline and subsequent recovery, while invested capital generally increased, with a notable decrease in the latest reported year. These movements impact the observed turnover of capital.
- Turnover of Capital (TO)
- The turnover of capital ratio began at 0.49 in 2021, increasing to 0.54 in 2022. This indicates improved efficiency in generating revenue from each dollar of invested capital. A slight decrease to 0.50 was observed in 2023. The ratio then rose marginally to 0.52 in 2024 before declining to 0.47 in 2025. This most recent decrease suggests a reduced efficiency in revenue generation relative to invested capital.
Revenues increased from US$39,211 million in 2021 to US$44,915 million in 2022, representing a substantial growth rate. Revenues then decreased slightly to US$42,857 million in 2023, remaining relatively stable at US$42,879 million in 2024, and increasing again to US$44,556 million in 2025. This revenue pattern influences the overall turnover of capital.
- Invested Capital
- Invested capital demonstrated a consistent upward trend from US$79,776 million in 2021 to US$85,573 million in 2023. However, a decrease to US$82,071 million was recorded in 2024. The most recent year, 2025, shows a significant increase to US$94,150 million. This increase in invested capital, particularly in 2025, likely contributed to the decline in the turnover of capital observed in that year, as revenue growth did not keep pace with the capital increase.
The interplay between revenue and invested capital suggests a dynamic relationship. While revenue generally increased over the period, the fluctuations in invested capital, especially the substantial increase in 2025, had a noticeable impact on the turnover of capital ratio. The decrease in TO in 2025 warrants further investigation to determine the underlying causes and potential implications for capital allocation efficiency.
Effective Cash Tax Rate (CTR)
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | ||||||
| Add: Cash operating taxes2 | ||||||
| Net operating profit before taxes (NOPBT) | ||||||
| Tax Rate | ||||||
| CTR3 | ||||||
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Merck & Co. Inc. | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2025 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × ÷ =
4 Click competitor name to see calculations.
The effective cash tax rate exhibited a fluctuating pattern over the five-year period. While net operating profit before taxes also fluctuated, the effective cash tax rate demonstrated a distinct trend of increasing volatility.
- Effective Cash Tax Rate (CTR)
- The effective cash tax rate began at 19.89% in 2021 and increased to 21.94% in 2022. This upward trend continued into 2023, reaching 24.94%, and peaked in 2024 at 26.49%. A significant decrease was then observed in 2025, with the rate falling to 16.63%. This represents the largest single-year change in the observed period.
Cash operating taxes generally followed the trend of net operating profit before taxes, though with some divergence. While both metrics decreased from 2022 to 2023, the decrease in cash operating taxes was proportionally larger, contributing to the increase in the effective cash tax rate. The increase in net operating profit before taxes from 2023 to 2024 was accompanied by a larger increase in cash operating taxes, further elevating the effective cash tax rate. The substantial decline in cash operating taxes in 2025, coupled with a modest increase in net operating profit before taxes, resulted in a considerable reduction in the effective cash tax rate.
- Relationship between NOPBT and CTR
- The relationship between net operating profit before taxes and the effective cash tax rate was not consistently linear. While an increase in net operating profit before taxes generally corresponded with an increase in cash operating taxes, the magnitude of these changes varied, influencing the effective cash tax rate. The largest fluctuations in the effective cash tax rate occurred when changes in cash operating taxes outpaced or lagged behind changes in net operating profit before taxes.
The volatility in the effective cash tax rate suggests potential changes in the company’s tax profile, including alterations in tax credits, deductions, or jurisdictional tax rates. Further investigation into the underlying drivers of these fluctuations would be beneficial.